Heart attack

December 13, 2017

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [TMZATX] encompassing Trimetazidine (TMZ) and Astaxanthin (ATX)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 14/December/2017, 12.14 am

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]
December 12, 2017

Molecular therapy for Cardiomyopathy: A pharmacological mixture encompassing Trimetazidine (TMZ) and Astaxanthin (ATX) [TMZATX] decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 13/December/2017,  1.00 am

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]
December 10, 2017

Molecular therapy for heart regeneration and repair: A therapeutic mix encompassing Trimetazidine (TMZ) and Astaxanthin (ATX) [TMZATX]  increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 10/December/2017, 10.45 pm

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]
December 9, 2017

Natural product-derived therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: β-Cryptoxanthin, Mangiferin and Glycyrrhetinic acid(CMG) decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 9/December/2017, 12.20 pm

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical […]